ANOTHER AUTISM CASE WINS IN VACCINE COURT

ANOTHER AUTISM CASE WINS IN VACCINE COURT

On February 12, the federal “Vaccine Court” in Washington issued a sweeping ruling in three highly touted “test cases” against families who claimed that their childrens’ autism had been caused by vaccines. The Special Masters in those three cases found that Petitioners failed to establish causation between MMR vaccines, the mercury-laced vaccine preservative thimerosal, and autism (the court decision, which is under appeal, deferred any finding on a thimerosal-only theory of causation). The rulings could have a significant precedential impact on some 5,000 families who opted to bring their cases in the Omnibus Autism Proceedings (OAP) hoping that the vaccine court would officially hold that the MMR vaccine or thimerosal had caused autism in their children.

The New York Times joined the government Health Agency (HRSA) and its big pharma allies hailing the decisions as proof that the scientific doubts about vaccine safety had finally been “demolished.” The US Department of Health and Human services said the rulings should “help reassure parents that vaccines do not cause autism.” The Times, which has made itself a blind mouthpiece for HRSA and a leading defender of vaccine safety, joined crowing government and vaccine industry flacks applauding the decisions like giddy cheerleaders, rooting for the same court that many of these same voices viscously derided just one year ago, after Hannah Poling won compensation for her vaccine induced autism.

But last week, the parents of yet another child with autism spectrum disorder (ASD) were awarded a lump sum of more than $810,000 (plus an estimated $30-40,000 per year for autism services and care) in compensation by the Court, which ruled that the measels-mumps-rubella (MMR) vaccine had caused acute brain damage that led to his autism spectrum disorder.

The family of 10-year-old Bailey Banks won their case quietly and without fanfare in June of 2007, but the ruling has only now come to public attention. In the remarkably clear and eloquent decision, Special Master Richard Abell ruled that the Banks had successfully demonstrated that “the MMR vaccine at issue actually caused the conditions from which Bailey suffered and continues to suffer.”

Bailey’s diagnosis is Pervasive Developmental Disorder — Not Otherwise Specified (PDD-NOS) which has been recognized as an autism spectrum disorder by CDC, HRSA and the other federal health agencies since at least the 1990s.

In his conclusion, Special Master Abell ruled that Petitioners had proven that the MMR had directly caused a brain inflammation illness called acute disseminated encephalomyelitis (ADEM) which, in turn, had caused the autism spectrum disorder PDD-NOS in the child:

The Court found that Bailey’s ADEM was both caused-in-fact and proximately caused by his vaccination. It is well-understood that the vaccination at issue can cause ADEM, and the Court found, based upon a full reading and hearing of the pertinent facts in this case, that it did actually cause the ADEM. Furthermore, Bailey’s ADEM was severe enough to cause lasting, residual damage, and retarded his developmental progress, which fits under the generalized heading of Pervasive Developmental Delay, or PDD [an autism spectrum disorder]. The Court found that Bailey would not have suffered this delay but for the administration of the MMR vaccine, and that this chain of causation was… a proximate sequence of cause and effect leading inexorably from vaccination to Pervasive Developmental Delay.

The Bailey decision is not an isolated ruling. We now know of at least two other successful ADEM cases argued in Vaccine Court. More significantly, an explosive investigation by CBS News has found that since 1988, the vaccine court has awarded money judgments, often in the millions of dollars, to thirteen hundred and twenty two families whose children suffered brain damage from vaccines. In many of these cases, the government paid out awards following a judicial finding that vaccine injury lead to the child’s autism spectrum disorder. In each of these cases, the plaintiffs’ attorneys made the same tactical decision made by Bailey Bank’s lawyer, electing to opt out of the highly charged Omnibus Autism Proceedings and argue their autism cases in the regular vaccine court. In many other successful cases, attorneys elected to steer clear of the hot button autism issue altogether and seek recovery instead for the underlying brain damage that caused their client’s autism.

Continued

 

Advertisements

Encephalitis and Encephalopathy (part 1)

Encephalitis

headVaccines containing Pertussis and Measles can cause encephalitis. Per the VICP guidelines; onset of encephalitis from Pertussis-containing vaccines is 24-48 hours, and between day five and fifteen for the MMR, M, MR and R vaccines.  
 
 
This is what the Vaccine Injury Compensation Program stated in the late 1980’s: 
 
The neurologic signs and symptoms of encephalopathy may be temporary with complete recovery or may result in various degrees of permanent impairment.  
 
Signs and symptoms such as high-pitched and unusual screaming, persistent inconsolable crying, and bulging fontanel are compatible with an encephalopathy, but in and of themselves are not conclusive evidence of encephalopathy. Encephalopathy usually can be documented by slow wave activity on an electroencephalogram. 
 
Today it states: 
 
The following clinical features alone, or in combination, do not demonstrate an acute encephalopathy or a significant change in either mental status or level of consciousness as described above: Sleepiness, irritability (fussiness), high-pitched and unusual screaming, persistent inconsolable crying, and bulging fontanelle. Seizures in themselves are not sufficient to constitute a diagnosis of encephalopathy. In the absence of other evidence of an acute encephalopathy, seizures shall not be viewed as the first symptom or manifestation of the onset of an acute encephalopathy.  

 

 

*This means it is no longer considered a contradiction to further vaccination.
 

An adverse reaction association does have a name and it is called: Crying Syndrome or Screaming Syndrome.  The scream is also known as cry-encephalitis. The cause is infection of the brain from the vaccine virus/bacteria. When the body is injected with virus/bacteria it can travel to the brain and cause encephalitis. Encephalitis can be a reaction to any vaccine but the DTP and DTaP is the most common.
 

What is interesting to note is that when encephalitis occurs following an illness, a doctor will treat it correctly. However, following a vaccination, a doctor will tell you it is a normal reaction to the vaccine and do nothing.

 

Workshop on neurologic complications of pertussis and pertussis vaccination
  

A multidisciplinary workshop held from September 29 to October 1, 1989, at Airlie House, Warrenton, Virginia, considered the neurologic complications of whooping cough and pertussis vaccine. Pertussis mortality in the U.S. in 2-3/1000 cases. Seizures occur in 1.9% of cases, and encephalopathy in 0.3%. Reviewing all data, it appears likely that a combination of one or more bacterial toxins, asphyxia, CO2 retention and loss of cerebral vascular autoregulation is responsible for neurologic symptoms. The timing of the encephalopathy suggests that it results from increased lysis of bacteria, and release of endotoxin. The encephalopathy is not confined to the paroxysmal phase. In evaluating side-reactions to the vaccine, the following must be kept in mind: 1. Vaccines are not standardized between manufacturers. 2. For a given manufacturer, vaccines are not standard from one batch to the next. 3. Unless the vaccine is properly prepared and refrigerated, its potency and reactivity varies with shelf life. In fact, the whole question of vaccine detoxification has never been systematically investigated. Listed in order of increasing severity, observed adverse reactions include irritability, persistent, unusually high pitched crying, somnolence, seizures, a shock-like “hypotensive, hyporesponsive” state, and an encephalopathy. Since the neurologic picture is not specific for pertussis vaccination, its temporal relationship to the vaccination is the critical variable for determining causation. Although the majority of seizures following pertussis vaccination are associated with fever, it was the consensus of the neurologists attending the workshop, that these do not represent febrile convulsions, but are non-benign convulsions. The incidence of post-vaccine encephalopathy is difficult to ascertain.

 

 Basically, the screaming is caused by the pain of the endotoxin in the vaccine getting into his brain. The screaming then causes a release of cortisol through the body which disrupts the immune system. It also causes the body temperature to rise. The intestines ph or acidity of changes, and bacteria called e-coli increases. If the amount gets high, that is when it can cause problems. The DTP is known to slow the function of the liver but it is not known which babies will be affected. Therefore, it becomes important to neutralize the curlin and take strain off the liver.

 

According to Drugs.com:

 

Diphtheria / Tetanus Toxoids / Acellular Pertussis Vaccine

( DTaP/Tdap ) Pronouncation: (diff-THEER-ee-uh/TET-ah-nus/ay-SELL-yoo-ler per-TUSS-uss vaccine) Class: Toxoid

 

Trade Names: 
Adacel(Tdap)

Active booster immunization against diphtheria, tetanus, and pertussis as a single dose in persons 11 to 64 yr of age.
– Injection 2 Lf units diphtheria toxoid, 5 Lf units tetanus toxoid, 3 mcg pertactin, 5 mcg filamentous hemagglutinin (FHA), 2.5 mcg detoxified pertussis toxins, 5 mcg fimbriae types 2 and 3 per mL.

 
Boostrix(Tdap)

Active booster immunization against diphtheria, tetanus, and pertussis as a single dose in persons 10 to 18 yr of age.
– Injection 2.5 Lf units diphtheria toxoid, 5 Lf units tetanus toxoid, 2.5 mcg pertactin, 8 mcg FHA, 8 mcg inactivated pertussis toxins per 0.5 mL
Daptacel
– Injection 15 Lf units diphtheria toxoid, 5 Lf units tetanus toxoid, 10 mcg pertussis toxoid, 5 mcg FHA, 3 mcg pertactin, 5 mcg fimbriae types 2 and 3 per 0.5 mL

 

Infanrix
– Injection 25 Lf units diphtheria, 10 Lf units tetanus toxoid, 25 mcg pertussis toxin, 25 mcg FHA, 8 mcg pertactin per 0.5 mL

 

Tripedia
– Injection 6.7 Lf units diphtheria toxoid, 5 Lf units tetanus toxoid, 46.8 mcg pertussis antigens (approximately 23.4 mcg each of inactivated pertussis toxin and FHA) per 0.5 mL

Daptacel , Infanrix , Tripedia (DTaP)

Active immunization against diphtheria, tetanus, and pertussis in infants and children 6 wk to 6 yr of age (prior to seventh birthday).

 

Per CDC, Tdap is for use in adults and children 10 yr of age and older, and DTaP is for use in infants and children younger than 7 yr of age.

Contraindications

Encephalopathy within 7 days of previous administration of DTP, Tdap, or DTaP that is not attributable to another cause; progressive neurologic disorders (eg, infantile spasms, uncontrolled epilepsy, progressive encephalopathy), in addition, pertussis vaccine should not be administered to persons with these conditions until a treatment regimen has been established and condition has stabilized; hypersensitivity to any component of the vaccine; history of serious allergic reaction temporarily associated with a previous dose of vaccine or any component of the vaccine.

 

Daptacel , Infanrix , Tripedia

Use in adults or children 7 yr of age and older; if contraindication to pertussis vaccine component occurs, substitute diphtheria and tetanus toxoids for pediatric use (DT) for each remaining dose; defer elective immunization procedures during outbreak of poliomyelitis because of risk of provoking paralysis.

 

It is recommended that the same brand of DTaP ( Daptacel , Infanrix , Tripedia ) be given for all doses in the immunization series because no data exist on the interchangeability of DTaP vaccines. Tdap vaccines ( Adacel , Boostrix ) are not interchangeable with DTaP vaccines.

 

 

Anticoagulants

Give DTaP/Tdap with caution to patients on anticoagulant therapy.

 

Immunosuppressants

May reduce vaccine’s efficacy.

 Influenza vaccine

To attribute causality of adverse reactions, do not give influenza vaccine within 3 days of pertussis vaccination.

Laboratory Test Interactions

None well documented.

 

Adverse Reactions

Cardiovascular

Boostrix

Myocarditis (postmarketing).

Daptacel

Cyanosis (postmarketing).

Infanrix

Cyanosis (postmarketing).

CNS

Adacel

Headache (44%); tiredness (30%); hyposthesia, paresthesia, vasovagal syncope (postmarketing).

 

Boostrix

Headache (43%); fatigue (37%); convulsion, encephalitis, facial palsy, paresthesia (postmarketing).

 

Daptacel

Fussines (76%); fretfulness (40%); drowsiness (33%); anorexia (11%); convulsions, febrile convulsion, grand mal convulsion, hypotonia, hypotonic-hyporesponsive episode, partial seizures, somnolence, screaming (postmarketing).

 

Infanrix

Drowsiness (38%); anorexia (12%); fussiness (9%); convulsions, crying, encephalopathy, hypotonia, hypotonic-hyporesponsive episode, irritability, somnolence (postmarketing).

 

Tripedia

Drowsiness (29%); irritability (25%); anorexia (10%); fussiness (6%); autism, convulsion, encephalopathy, grand mal convulsion, hypotonia, neuropathy, somnolence (postmarketing).

Dermatologic

Adacel

Rash (3%); pruritus, urticaria (postmarketing).

 

Boostrix

Exanthem, Henoch-Schonlein purpura, rash (postmarketing).

 Infanrix

Erythema, pruritus, rash, urticaria (postmarketing).

GI

Adacel

Nausea (13%); diarrhea (10%); vomiting (5%).

 Boostrix

GI symptoms including abdominal pain, diarrhea, nausea, vomiting (26%).

 Daptacel

Vomiting (7%); diarrhea, nausea (postmarketing).

 Infanrix

Vomiting (7%); diarrhea, intussusception (postmarketing).

 Tripedia

Vomiting (5%).

Hematologic-Lymphatic

Adacel

Lymph node swelling (7%).

 

Boostrix

Lymphadenitis, lymphadenopathy (postmarketing).

 

Infanrix

Idiopathic thrombocytopenic purpura, lymphadenopathy, thrombocytopenia (postmarketing).

 

Tripedia

Idiopathic thrombocytopenic purpura (postmarketing).

Hypersensitivity

Boostrix

Anaphylactic reaction, arthus-type hypersensitivity.

 

Daptacel

Allergic reaction, anaphylactic reaction (edema, face edema, face swelling, generalized rash and other types of rash, pruritus), hypersensitivity (postmarketing).

 

Infanrix

Anaphylactic reaction, hypersensitivity (postmarketing).

 

Tripedia

Anaphylactic reaction (postmarketing).

Local

Adacel

Pain (78%); erythema (25%); swelling (21%); injection-site bruising, sterile abscess

(postmarketing).

 

Boostrix

Pain (75%); redness (48%); swelling (39%); increase in arm circumference (28%); induration, inflammation, local reaction, mass, nodule, warmth (postmarketing).

 

Daptacel

Tenderness (50%); increased arm circumference (30%); redness (17%); swelling (12%); cellulitis, injection-site abscess, injection-site mass, injection-site nodule, injection-site pain, injection-site rash.

 

Infanrix

Redness (59%); swelling (50%); pain (27%); injection-site reactions (postmarketing).

 

Tripedia

Redness (33%); swelling (28%); pain (21%).

Musculoskeletal

Adacel

Body ache or muscle weakness (30%); sore and swollen joints (11%); muscle spasms, myelitis, myositis (postmarketing).

 

Boostrix

Arthralgia, back pain, myalgia (postmarketing).

 

Infanrix

Limb swelling (postmarketing).

Miscellaneous

Adacel

Chills (15%); fever (5%).

 

Boostrix

Fever (14%); insulin-dependent diabetes mellitus (postmarketing).

 

Daptacel

Crying (59%); decreased activity (51%); fever (24%).

 

Infanrix

Fever (7%); cellulitis, ear pain, respiratory tract infection, sudden infant death syndrome (postmarketing).

 

Tripedia

Fever (25%); apnea, sudden infant death syndrome (postmarketing).

 

Pregnancy

Category C .

Lactation

Undetermined.

Children

Adacel

Safety and efficacy not established in children younger than 11 yr of age.

 Boostrix

Not indicated for use in patients younger than 10 yr of age or older than 18 yr of age.

 

Daptacel , Infanrix , Tripedia

Safety and efficacy in infants younger than 6 wk of age not established; contraindicated for persons 7 yr of age and older.

Elderly

Adacel

Safety and efficacy not established in individuals 65 yr of age and older.

Special Risk Patients

If any of the following occurs in temporal relation with receipt of either whole-cell pertussis DTP or DTaP, carefully consider decision to administer subsequent doses of vaccine containing pertussis component: temperature of at least 105°F within 48 h not caused by another identifiable cause; collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 h; persistent inconsolable crying lasting at least 3 h occurring within 48 h; or convulsions, with or without fever, occurring within 3 days. If the decision is made to withhold pertussis component, continue immunization with DT (Td if 7 yr of age and older). If Guillain-Barré syndrome occurs within 6 wk of receipt of prior vaccine containing tetanus toxoids, base decision to give subsequent doses of DTaP or any vaccine containing tetanus toxoids on potential benefits versus risks. Patients who experience serious Arthus-type hypersensitivity reactions following a prior dose of tetanus toxoids usually have high serum tetanus antitoxin levels and should not be given Td or DTaP vaccines or even emergency doses of Td more frequently than every 10 yr, even if wound is neither clean nor minor.

Bleeding disorders

Use with caution in patients with bleeding disorders (eg, thrombocytopenia, hemophilia) or receiving anticoagulant therapy.

Convulsions/CNS disorders

Family history of seizures or other CNS disorders is not a contraindication to pertussis vaccine.

Febrile illness or acute infection

Defer immunization during course of illness. Minor respiratory illness, such as mild upper respiratory tract infection, is usually not a reason to defer immunization.

Immunodeficiency

May have diminished antibody response; defer immunization, if possible, until immunocompetency is restored.

Latex sensitivity

Stoppers for Daptacel and Tripedia vials, and tip cap and rubber plunger of Infanrix and Boostrix needleless prefilled syringes contain dry natural latex rubber that may cause allergic reactions in latex-sensitive individuals.

 

Measles, Mumps, and Rubella (MMR) vaccine

Brand Names: M-M-R II

 

What should I discuss with my healthcare provider before receiving this vaccine?

You should not receive this vaccine if you are allergic to:

  • eggs;
  • gelatin;
  • neomycin (Mycifradin, Neo-Fradin, Neo-Tab); or
  • if you have ever had a life-threatening allergic reaction to any vaccine containing measles, mumps, or rubella.
  •  

You should also not receive this vaccine if you have:

  • a chronic disease such as asthma or other breathing disorder, diabetes, kidney disease, or blood cell disorders such as anemia;
  • severe immune suppression caused by disease (such as cancer, HIV, or AIDS), or by receiving certain medicines such as steroids, chemotherapy or radiation; or
  • if you are pregnant.
  •  

Before receiving this vaccine, tell the doctor if you have:

  • thrombocytopenia purpura (easy bruising or bleeding);
  • active tuberculosis infection;
  • a history of seizures;
  • a neurologic disorder or disease affecting the brain (or if this was a reaction to a previous vaccine);
  • a weak immune system caused by disease, bone marrow transplant, or by using certain medicines or receiving cancer treatments;
  • if you have received an immune globulin or other blood product within the past year; or
  • if you have received a previous MMR vaccine within the past 28 days (4 weeks).
  •  

You can still receive a vaccine if you have a cold or fever. In the case of a more severe illness with a fever or any type of infection, wait until you get better before receiving this vaccine.

You should not receive a measles, mumps, and rubella vaccine if you are pregnant. Wait until after your child is born to receive the vaccine.

Avoid becoming pregnant for at least 3 months after receiving a measles, mumps, and rubella vaccine.

Do no not receive this vaccine without telling your doctor if you are breast-feeding a baby.

What should I avoid before or after receiving this vaccine?

Do not receive another “live” vaccine such as oral polio, yellow fever, or varicella (chickenpox) for at least 4 weeks after you have received the measles, mumps, and rubella vaccine. The other live vaccine may not work as well during this time, and may not fully protect you from disease.

Measles, mumps, and rubella vaccines side effects

You should not receive a booster vaccine if you had a life-threatening allergic reaction after the first shot. Keep track of any and all side effects you have after receiving this vaccine. When you receive a booster dose, you will need to tell the doctor if the previous shots caused any side effects.

Becoming infected with measles, mumps, or rubella is much more dangerous to your health than receiving the vaccine to protect against these diseases. Like any medicine, this vaccine can cause side effects, but the risk of serious side effects is extremely low.

 

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have any of these serious side effects:

  • problems with hearing or vision;
  • extreme drowsiness, fainting;
  • easy bruising or bleeding, unusual weakness;
  • seizure (black-out or convulsions); or
  • high fever (within a few hours or a few days after the vaccine).
  •  

Less serious side effects include:

  • redness, pain, swelling, or a lump where the shot was given;
  • headache, dizziness;
  • low fever;
  • joint or muscle pain; or
  • nausea, vomiting, diarrhea.
  •  

Side effects other than those listed here may also occur. Contact your doctor about any side effect that seems unusual or that is especially bothersome.

What other drugs will affect measles, mumps, and rubella vaccine?

Before receiving this vaccine, tell the doctor about all other vaccines you have recently received.

Also tell the doctor if you have recently received drugs or treatments that can weaken the immune system, including:

  • an oral, nasal, inhaled, or injectable steroid medicine;
  • medications to treat psoriasis, rheumatoid arthritis, or other autoimmune disorders, such as azathioprine (Imuran), efalizumab (Raptiva), etanercept (Enbrel), leflunomide (Arava), and others; or
  • medicines to treat or prevent organ transplant rejection, such as basiliximab (Simulect), cyclosporine (Sandimmune, Neoral, Gengraf), muromonab-CD3 (Orthoclone), mycophenolate mofetil (CellCept), sirolimus (Rapamune), or tacrolimus (Prograf).
  •  

If you are using any of these medications, you may not be able to receive the vaccine, or may need to wait until the other treatments are finished.

There may be other drugs that can affect this vaccine. Tell your doctor about all the prescription and over-the-counter medications you have received. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.

 

ProQuad -Measles, Mumps, Rubella, and Varicella Vaccine

Do NOT use ProQuad if:

  • you are allergic to any ingredient in ProQuad , including gelatin
  • you have had a severe allergic reaction (eg, severe rash, hives, difficulty breathing, dizziness) to neomycin
  • you have a weakened immune system (eg, advanced HIV, AIDS, decreased gamma globulin levels, decreased white blood cell levels), blood problems, cancer affecting the blood or bone marrow (eg, leukemia), fever, or active or untreated tuberculosis (TB)
  • you are pregnant
  • you are taking an immunosuppressant (eg, cyclosporine) or a salicylate (eg, aspirin)

Contact your doctor or health care provider right away if any of these apply to you.

Before using ProQuad :

Some medical conditions may interact with ProQuad . Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

  • if you are planning to become pregnant or are breast-feeding
  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement
  • if you have allergies to medicines, foods, or other substances
  • if you are allergic to eggs
  • if you have an infection, a tumor, HIV, low blood platelet levels, a history of seizures or head injury, or a family history of seizures or immune system weakness
  • if you have had a recent blood or plasma transfusion or have received immune globulin or a tuberculin test
  • if you have been exposed to measles, mumps, rubella, or chickenpox
  • if you have a history of tuberculosis

Some MEDICINES MAY INTERACT with ProQuad . Tell your health care provider if you are taking any other medicines, especially any of the following:

  • Corticosteroids (eg, prednisone) or immunosuppressants (eg, cyclosporine) because the effectiveness of ProQuad may be decreased
  • Salicylates (eg, aspirin) because the risk of side effects may be increased

This may not be a complete list of all interactions that may occur. Ask your health care provider if ProQuad may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

Important safety information:

  • ProQuad may cause drowsiness or dizziness. Do not drive, operate machinery, or do anything else that could be dangerous until you know how you react to ProQuad . Using ProQuad alone, with certain other medicines, or with alcohol may lessen your ability to drive or perform other potentially dangerous tasks.
  • This medicine may decrease the effectiveness of tuberculin tests. If you are scheduled to have a tuberculin test within 6 weeks after receiving this vaccination, contact your doctor. You may need to reschedule your tuberculin test.
  • Avoid contact with individuals with weakened immune systems, pregnant women who have not had chickenpox, and newborns whose mothers have not had chickenpox for 6 weeks after receiving this vaccination.
  • Avoid use of salicylates (eg, aspirin) for 6 weeks after receiving this vaccination.
  • Keep written documentation of all vaccinations received to help avoid unnecessary doses. Be sure that your doctor knows the dates that you have received other vaccinations.
  • This vaccine may not guarantee protection against measles, mumps, rubella, or chickenpox. Discuss any questions or concerns with your doctor.
  • Adult women may experience joint pain 2 to 4 weeks after receiving this injection. This usually lasts only a short time. However, these symptoms have persisted for months or, rarely, years.
  • ProQuad contains albumin, which comes from human blood. There is an extremely rare risk of developing a viral disease, or a central nervous system disease called Creutzfeldt-Jakob disease. No cases of viral diseases or Creutzfeldt-Jakob disease from albumin have been identified.
  • Use ProQuad with extreme caution in CHILDREN younger than 12 months of age. Safety and effectiveness in this age group have not been confirmed.
  • PREGNANCY and BREAST-FEEDING: Do not use ProQuad if you are pregnant. If you suspect that you could be pregnant, contact your doctor immediately. After receiving ProQuad , do not become pregnant for at least 3 months without checking with your doctor. It is unknown if ProQuad is excreted in breast milk. Do not breast-feed while using ProQuad .

Possible side effects of ProQuad :

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Diarrhea; dizziness; fever; general unwell feeling; headache; irritability; mild rash; muscle or joint ache or pain; nausea; pain, tenderness, soreness, or swelling at the injection site; tiredness; vomiting.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); fainting; loss of coordination; mental or mood changes; numbness or tingling in the fingers or toes; red, swollen, blistered, or peeling skin; seizures; unusual bruising or bleeding; vision or hearing changes.

This is not a complete list of all side effects that may occur. If you have questions or need medical advice about side effects, contact your doctor or health care provider. You may report side effects to the FDA at 1-800-FDA-1088 (1-800-332-1088) or at http://www.fda.gov/medwatch.

 

Encephalitis and Encephalopathy

 

 

Encephalitis is inflammation of the brain. The inflammation is caused either by an infection invading the brain (infectious); or through the immune system attacking the brain in error (post-infectious / autoimmune encephalitis).

Encephalitis is different from meningitis. Meningitis means inflammation of the protective layers that cover the brain. Sometimes patients have both meningitis and encephalitis and this is called meningoencephalitis.

 

Encephalopathy is a term for any diffuse disease of the brain that alters brain function or structure. Encephalopathy may be caused by infectious agent (bacteria, virus, or prion), metabolic or mitochondrial dysfunction, brain tumor or increased pressure in the skull, prolonged exposure to toxic elements (including solvents, drugs, radiation, paints, industrial chemicals, and certain metals), chronic progressive trauma, poor nutrition, or lack of oxygen or blood flow to the brain. The hallmark of encephalopathy is an altered mental state. Depending on the type and severity of encephalopathy, common neurological symptoms are progressive loss of memory and cognitive ability, subtle personality changes, inability to concentrate, lethargy, and progressive loss of consciousness. Other neurological symptoms may include myoclonus (involuntary twitching of a muscle or group of muscles), nystagmus (rapid, involuntary eye movement), tremor, muscle atrophy and weakness, dementia, seizures, and loss of ability to swallow or speak. Blood tests, spinal fluid examination, imaging studies, electroencephalograms, and similar diagnostic studies may be used to differentiate the various causes of encephalopathy.

 

 

  Pertussis vaccination and epilepsy–an erratic history, new research and the mismatch between science and social policy.

 

For over 50 years, concerns have been raised about the risk of pertussis vaccine-induced childhood encephalopathy and epilepsy. This article reviews the scientific literature, and the social and historical context in which the scientific, public health and societal views have not always been aligned. Large-scale studies of this issue have produced conflicting results, although the recent consensus is that the risk of vaccine-induced encephalopathy and/or epilepsy, if it exists at all, is extremely low. Risk estimates in the literature have included: risk of a febrile seizure 1 per 19,496 vaccinations; risk of an afebrile seizure 1 per 76,133 vaccinations; risk of encephalopathy after pertussis infection nil-3 cases per million vaccinations. A recent study showed that encephalopathy in 11 out of the 14 children studied, although previously attributed to vaccination, was in fact due an inherited genetic defect of the SCNIA gene that codes for the voltage gated neuronal sodium channel. This study is important because it provides a solid alternative explanation for the perceived pertussis vaccine-encephalopathy association. The interesting possibility is raised that the encephalopathy apparently due to pertussis itself may, in some cases, be due to an SCNIA mutation. It may also, by analogy, shed some light on the continuing debate about other serious long-term adverse effects of vaccination in general.

 

 To be continued…the autism connection, post-vaccinal encephalomyelitis, the rise in neurological disorders…

CDC-sponsored MMR study supports Wakefield’s findings

CDC-sponsored MMR study supports Wakefield’s findings

By F. Edward Yazbak MD, FAAP

The CDC tried again and …failed again

But this time, it validated Andrew Wakefield’s findings

 

 

 

 

 

 

*The following critique was to be published on the Web Site of the Vaccine Autoimmune Project on Monday September 15, 2008. Unfortunately the VAP web site was the target of malicious hacking. I am grateful to John and Jackie Fletcher for their invitation to feature it on JABS

MMR Vaccine, Measles, Mumps, Rubella

Dr Richard Halvorsen answers the big questions about MMR, Vaccines and Diseases

MMR Vaccine

MMR vaccine is it safe or effective? You be the judge based on the medical literature that is available to you.

 

 The MMR vaccine consists of 3 live viruses for Measles, Mumps and Rubella. The MMR-V has live chicken pox added to the mix. It contains a weakened or partially inactivated, live measles virus which is grown in cell cultures of a chick embryo. A weakened live strain of mumps virus is grown in cell cultures of a chick embryo. A weakened Wistar RA 27/3 strain of live attenuated rubella virus which is grown in human diploid cell (W-38) culture originating from the tissues of a fetus aborted in 1964. There is no preservative such as Thimerosal(mercury). It contains the antibiotic neomycin, and Sorbitol and Hydrolyzed Gelatin as stabilizers. All three live viruses are available as single vaccines but doctors will most often tell you they are not available, or refuse to give them as separate vaccines.

 

 How it can shed to others:

 

Mumps vaccine virus genome is present in throat swabs obtained from uncomplicated healthy recipients. 
  
Seven children were followed for up to 42 days post-vaccination with live mumps vaccine and 37 throat swabs were obtained serially. Viral genomic RNA was detected by reverse transcription-polymerase chain reaction (RT-PCR) in the phosphoprotein (P) and hemagglutinin-neuraminidase (HN) regions. Virus isolation was also attempted. Genomic differentiation of detected mumps virus genome was performed by sequence analysis and/or restriction fragment length polymorphism (RFLP). No adverse reaction was observed in these children. Although mumps virus was not isolated from any of the samples, viral RNA was detected in four samples from three vaccine recipients, 18, 18 and 26, and 7 days after vaccination, respectively. Detected viral RNA was identified as the vaccine strain. Our data suggests that vaccine virus inoculated replicates in the parotid glands but the incidence of virus transmission from recipients to other susceptible subjects should be low. 

 

Detection of measles vaccine in the throat of a vaccinated child. 
   
Measles vaccine is widely used, most often in association with mumps and rubella vaccines. We report here the case of a child presenting with fever 8 days after vaccination with a measles-mumps-rubella vaccine. Measles virus was isolated in a throat swab taken 4 days after fever onset. This virus was then further genetically characterised as a vaccine-type virus. Fever occurring subsequent to measles vaccination is related to the replication of the live attenuated vaccine virus. In the case presented here, the vaccine virus was isolated in the throat, showing that subcutaneous injection of an attenuated measles strain can result in respiratory excretion of this virus. 
 

 Reactions to MMR Vaccine are Triphasic:

Any reactions that are 6 – 14 days are the measles component and usually show as temperature and rash, and sometimes seizures.
The second phase is between 11 and 32 days which is the mumps components. This can consist of temperature, seizures, and acquiring mumps.
The third phase can occur within the first 0 – 30 days, and is the rubella component. It can cause joint pain or arthritis. This most often occurs in adolescents and adults, and perhaps babies, but they wouldn’t be able to tell you.

 

  
 Delaying MMR until a child is older makes it ‘safer’? The reality is there is no ‘safe’ time to delay as reactions can occur at any time if the conditions are right. A 6 year old, or 12 year old child, or a young adult can have serious reactions or death associated with the vaccine. Parents can opt to have titer tests done first.
 

 

 

The CDC, AAP, FDA, NIH, etc., can say what they wish to the public and promote MMR and its safety, continue to put their heads in the sand, and talk out their rear ends, but let’s get real and look at some of the studies:


AAP Study: Relationship b/t MMR & Encephalitis w/ Perm. Brain Injury or Death.

  

 

The purpose of this study of claims submitted to the National Vaccine Injury Compensation Program is to determine whether or not there is evidence for a causal relationship between the first dose of a currently used attenuated measles vaccine, MR, MMR, mumps, or rubella vaccine and encephalopathy of undetermined cause with permanent brain injury or death that occurred within 15 days after administration.
A total of 403 [compensation] claims of encephalopathy and/or seizure disorder after measles, MR, MMR, mumps, or rubella vaccination were identified during this 23-year period [1970-1993]. Of these claims, 48 (25 males and 23 females) met the inclusion criteria and acquired an acute encephalopathy of undetermined cause 2 to 15 days after receiving measles vaccine, MR, or MMR. This acute encephalopathy was followed by permanent brain impairment or death. The patients ranged in age from 10 months to 49 months, with a median age of 15 months and a mean age of 17.5 months.
Results
A total of 48 children, ages 10 to 49 months, met the inclusion criteria after receiving measles vaccine, alone or in combination. Eight children died, and the remainder had mental regression and retardation, chronic seizures, motor and sensory deficits, and movement disorders. The onset of neurologic signs or symptoms occurred with a nonrandom, statistically significant distribution of cases on days 8 and 9. No cases were identified after the administration of monovalent mumps or rubella vaccine.
Conclusions
This clustering suggests that a causal relationship between measles vaccine and encephalopathy may exist as a rare complication of measles immunization
 
 
  Former science chief: ‘MMR fears coming true’

 He said he has seen a “steady accumulation of evidence” from scientists worldwide that the measles, mumps and rubella jab is causing brain damage in certain children.

But he added: “There are very powerful people in positions of great authority in Britain and elsewhere who have staked their reputations and careers on the safety of MMR and they are willing to do almost anything to protect themselves.”
 In the late Seventies, Dr Fletcher served as Chief Scientific Officer at the DoH and Medical Assessor to the Committee on Safety of Medicines, meaning he was responsible for deciding if new vaccines were safe.

He first expressed concerns about MMR in 2001, saying safety trials before the vaccine’s introduction in Britain were inadequate.
Now he says the theoretical fears he raised appear to be becoming reality.
He said the rising tide of autism cases and growing scientific understanding of autism-related bowel disease have convinced him the MMR vaccine may be to blame.
“Clinical and scientific data is steadily accumulating that the live measles virus in MMR can cause brain, gut and immune system damage in a subset of vulnerable children,” he said. “There’s no one conclusive piece of scientific evidence, no ‘smoking gun’, because there very rarely is when adverse drug reactions are first suspected. When vaccine damage in very young children is involved, it is harder to prove the links.
“But it is the steady accumulation of evidence, from a number of respected universities, teaching hospitals and laboratories around the world, that matters here. There’s far too much to ignore. Yet government health authorities are, it seems, more than happy to do so.”

 “Yet there has been a tenfold increase in autism and related forms of brain damage over the past 15 years, roughly coinciding with MMR’s introduction, and an extremely worrying increase in childhood inflammatory bowel diseases and immune disorders such as diabetes, and no one in authority will even admit it’s happening, let alone try to…

 

 

   Very informative presentation:

The Seat of the Soul The Origins of the Autism Epidemic

 

Sally Beck wrote an article on the study at Wake Forest University School of Medicine in North Carolina titled Scientists fear MMR link to autism”, which was similar to the one reported by Andrew Wakefield, MD, in 1998.


In the American study, 275 children with regressive autism and bowel disease
were evaluated. Of the 82 children completely tested, 70 proved positive for
the measles virus. Beck quoted Stephen Walker, MD, the team leader as
saying, “Of the handful of results we have in so far, all are vaccine strain
and none are wild measles. This research proves that in the gastrointestinal
tract of a number of children, who have been diagnosed with regressive
autism, there is evidence of measles virus.”

Very little was reported about the Wake Forest research in the American media. But with no surprise, immediately afterwards, this came out:

Reuters Health Information in New York published an account of a different study headlined No Evidence of Measles Virus in MMR-Vaccinated Autistic Children.” It said “contrary to the findings of some earlier studies, measles virus genetic material was not detected in the blood of MMR-vaccinated autistic children with development regression, according to a report in the Journal of Medical Virology for May.”

 

 

 
So here we have two studies that are contradictory. What are the differences between the two studies?
 
 
 
 In the U.S. study, measles virus genomic RNA was actually found in the gut of 70 affected children and the viral results of another 200 children with typical gut pathology are still pending.

In the U.K. study, the researchers “could not detect” measles virus genetic material in the blood of 15 MMR-vaccinated children with autism.

It is essential to also point out that the above-mentioned M.A. Afzal is not N.A. Afzal, a pediatric gastroenterologist attached to the Centre for Pediatric Gastroenterology at The Royal Free Hospital, London, U.K. It was at the Royal Free Hospital that Andrew Wakefield practiced gastroenterology for years and where he was the shining star before he dared to “rock the boat” and was forced to resign. It is also at the Royal Free and University College Medical School in London that Brent Taylor, one of Wakefield’s most vocal critics, is professor of community pediatrics. N.A. Afzal published his first study with the Royal Free team in December 2002.  He published two more studies in 2004 and one in 2005. The abstracts of all four studies did not contain any reference to autism and vaccines.

M.A. Afzal, on the other hand, is a member of the virology department at the National Institute for Biological Standards and Control (NIBSC). The Institute is a respected multi-disciplinary scientific establishment with national and international roles in the standardization and control of biological substances including viral and bacterial vaccines. Since 1976, the institute has been directly funded by the United Kingdom Health Departments.

But back to M.A. Afzal of the NIBSC, who according to Reuters was certain in 2006 that the measles virus material genuinely did not exist in the patients ‘ blood samples because he and his team did not find it. He must have been aware that a Japanese team from Tokyo University led by H. Kawashima had found the same “genetic material” in the blood of children with autism in 2000: “In order to characterize the strains that may be present, we have carried out the detection of measles genomic RNA in peripheral mononuclear cells (PBMC) in eight patients with Crohn’s disease, three patients with ulcerative colitis, and nine children with autistic enterocolitis…”

Kawashima discovered and reported that “the sequences obtained from the children with autism were consistent with being vaccine strains” and that the results were concordant with the exposure history of those children.

 

 

So how come Team Tokyo found vaccine-strain measles virus genomic RNA in peripheral mononuclear cells of vaccinated autistic children in 2000 and Team U.K. found nothing in 2006? The answer to that perplexing and rather sensitive question may be in a very interesting study that was published in the Journal of Medical Virology in May 2003, titled appropriately “Comparative evaluation of measles virus-specific RT-PCR methods through an international collaborative study” and authored by both Afzal and Kawashima, in addition to renowned experts A.D. Osterhaus, S.L. Cosby, L. Jin, J. Beeler and K. Takeuchi.

 

 

Measles infection and inflammatory bowel disease


Afzal and colleagues published “Absence of detectable measles virus genome sequence in inflammatory bowel disease tissues and peripheral blood lymphocytes” in the Journal of Medical Virology.  According to the authors, in spite of using a “highly sensitive measles-specific RT-PCR-nested PCR system,” they failed to detect the presence of measles virus in 93 colon biopsies and 31 peripheral blood lymphocyte preparations, examined and obtained from patients with IBD and non-inflammatory controls.

It seems from the above that M.A. Afzal was looking for evidence of viral presence in the colon (large intestine) and did not find any. Wakefield had better luck, a little later, when he looked for such evidence in the ileum. Afzal was certainly aware that the children tested by the Royal Free Team had ileal lymphonodular hyperplasia.

 
(Lancet. 1998.Feb 28; 351(9103): 646-7. PMID: 9500326) (J Med Virol. 2003 May; 70(1): 171-6. PMID: 12629660) (Absence of measles-virus genome in inflammatory bowel disease. Ital J Gastroenterol Hepatol. 1998 Aug; 30(4): 378-82. PMID: 9789132)  (Absence of detectable measles virus genome sequence in inflammatory bowel disease tissues and peripheral blood lymphocytes. J Med Virol. 1998 Jul; 55(3): 243-9.)
 
 
 
 

 

  Measles virus and Crohn’s disease

In April 1999, Wakefield, Montgomery and Pounder published “Crohn’s disease: the case for measles virus.”  They reported, “We and others have suggested that measles virus may be causally related to Crohn’s disease, and that the associated risk is an atypical pattern of exposure. The data for Crohn’s disease suggest that persistent infection may follow early low dose exposure and low zone immunological tolerance. The changing pattern of measles virus exposure this century would be consistent with a shift toward lower dose of infection. Such an exposure would also be consistent with persistence of the virus at very low copy number within discrete foci of granulomatous inflammation..”  Afzal, Minor, Armitage and Gosh published “Measles virus and Crohn’s disease” in June of the same year.  

(2000: MMR Wakefield AJ, Montgomery SM, Pounder RE. Crohn’s disease: the case for measles virus. Ital J Gastroenterol Hepatol. 1999 Apr; 31(3): 247-54. Review. PMID: 10379489.)  (Afzal MA, Minor PD, Armitage E, Ghosh S. Measles virus and Crohn’s disease. Gut. 1999 Jun; 44(6): 896-7. PMID: 10375297 Safety Review.)

Measles, mumps, rubella vaccine: through a glass, darkly,” Wakefield and Montgomery reviewed the safety testing of MMR vaccine or lack thereof.

(Potential viral pathogenic mechanism for new variant inflammatory bowel disease. Mol Pathol. 2002 Apr; 55(2): 84-90. PMID: 11950955)

In “Clinical safety issues of measles, mumps and rubella vaccines,” Afzal, Minor and Schild did not directly respond but essentially reviewed all the studies that had been done by the anti-Wakefield camp and had failed to identify the presence of measles virus genomic RNA in patients with IBD. In the available abstract, M.A. Afzal stated, “Based on the published data reviewed here, it can be concluded that there is no direct association between measles virus or measles vaccines and the development of Crohn’s disease, a conclusion which is supported by most epidemiological findings.” (Bull World Health Organ. 2000; 78(2): 199-204. Review. PMID: 10743285)

As to the safety of the MMR vaccine, the Cochrane MMR Review: “The design and reporting of safety outcomes in MMR vaccine studies, both pre- and post-marketing, are largely inadequate.”

 

April 2002

 

In “Potential viral pathogenic mechanism for new variant inflammatory bowel disease,” Uhlmann and associates, including Wakefield, published results of their meticulous research. It revealed that “75 of 91 patients with a histologically confirmed diagnosis of ileal lymphonodular hyperplasia and enterocolitis were positive for measles virus in their intestinal tissue compared with five of 70 control patients. Measles virus was identified within the follicular dendritic cells and some lymphocytes in foci of reactive follicular hyperplasia. The copy number of measles virus ranged from one to 300,00 copies/ng total RNA.” The authors concluded, “The data confirm an association between the presence of measles virus and gut pathology in children with developmental disorder.” 

 

(Dig Dis Sci. 2000. Apr; 45(4): 723-9.)

 

March 2008-

 

 

MMR: Vaccine can cause blood disorder

 There’s more bad news for advocates of the MMR (measles-mumps-rubella) vaccine with the discovery this week that it can cause a blood disorder.  Researchers have found that it may trigger immune thrombocytopenic purpura (ITP), an immune system malfunction that destroys the body’s own blood platelets. The effect seems to last for an average of seven days, during which time the child’s platelet count could fall.

The risk is relatively low, say researchers, and one case of ITP will be caused per 40,000 vaccinations.  The risk appears to last for up to 42 days after vaccination.
Researchers from Kaiser Permanente Colorado, Denver analyzed the health profiles of more than 1 million children who had been vaccinated.  Of these, 259 developed ITP, and they reckon the vaccine was responsible for 76 per cent of these cases.
(Source: Pediatrics, 2008; 121: e687-e692).

 
 

 

Persistence of Measles, Mumps, and Rubella Antibodies in an MMR-Vaccinated Cohort: A 20-Year Follow-up.

 

Conclusions.  A high rate of seropositivity was found 20 years after the first MMR dose, particularly for rubella and measles. Our results show that MMR vaccine–induced antibodies wane significantly after the second dose. According to epidemiological data, the protection induced by MMR vaccination in Finland seems to persist at least until early adulthood. However, the situation requires constant vigilance. (The Journal of Infectious Diseases 2008;197:950–956)

 

 MMR vaccine and Tylenol Use:

 Acetaminophen (paracetamol) use, measles-mumps-rubella vaccination, and autistic disorder: The results of a parent survey.


The present study was performed to determine whether acetaminophen (paracetamol) use after the measles-mumps-rubella vaccination could be associated with autistic disorder. This case-control study used the results of an online parental survey conducted from 16 July 2005 to 30 January 2006, consisting of 83 children with autistic disorder and 80 control children. Acetaminophen use after measles-mumps-rubella vaccination was significantly associated with autistic disorder when considering children 5 years of age or less (OR 6.11, 95% CI 1.42-26.3), after limiting cases to children with regression in development (OR 3.97, 95% CI 1.11-14.3), and when considering only children who had post-vaccination sequelae (OR 8.23, 95% CI 1.56-43.3), adjusting for age, gender, mother’s ethnicity, and the presence of illness concurrent with measles-mumps-rubella vaccination. Ibuprofen use after measles-mumps-rubella vaccination was not associated with autistic disorder. This preliminary study found that acetaminophen use after measles-mumps-rubella vaccination was associated with autistic disorder.
 We know that acetaminophen impairs the glutathione pathways, as well as hormone balance. The glutathione pathways are the same ones involved in naturally “chelating” out metals. Acetaminophen can also suppress the immune system and when given with Gardasil, results in a lower antibody development. Thus it can crash some aspects of the immune system. So, if autism results from a situation where if the immune system is suppressed and nutrition isn’t quite right, the body is not able to clear out heavy metals, and then anything can make that situation worse and contribute to the problem. This study does not mean that MMR is not implicated, but that Acetaminophen was part of an overall negative equation.

 

Proquad

 Children suffered higher rates of fever-related convulsions when they received the combination vaccine Proquad instead of two separate shots. The study (Nicola P. Klein, MD, PhD, a research scientist from Northern California Kaiser Permanente and co-director of the Kaiser Permanente Vaccine Study Center) which included children ages 12 months through 23 months, found the rate of seizures was twice as high in toddlers who got ProQuad, compared with those who got separate shots for MMR and Chicken Pox (Varicella vaccine).

ProQuad was licensed in 2005 but had suspended production because of manufacturing problems. There is five times more chickenpox antigen in the ProQuad shot than in the Varicella vaccine.

 

ACIP approves MMRV vaccine revision 2008

Possible increased risk for febrile seizures found among children aged 12 to 23 months after receipt of MMRV vaccine.

“MMRV vaccine has not been widely distributed in the United States since June 2007 and is not expected to be available again until 2009; however, some providers might still have some supply in stock,” she said. “As far as postvaccination safety monitoring, in October 2007 following FDA review of adverse event reports submitted to VAERS and Merck’s worldwide adverse experience system, MMRV vaccine labeling was updated to include convulsion and febrile seizures among adverse reactions postvaccination.”

Quick Picks:

 

According to The New England Journal of Medicine, 60 percent of all measles cases among American school children between 1985 and 1986 occurred in those who were vaccinated.

  The Journal of the American Medical Association published a study in 1986, which showed that among 235 cases of student measles reported in Dane County, Wisconsin; more than 96 percent had received a measles vaccine. A study reported in Morbidity and Mortality Weekly Report found that 58 percent of 1600 cases of measles in Quebec, Canada, in 1989 occurred in those who had already been vaccinated.  The World Health Organization has conceded that those administered the measles vaccine have a 14 times greater likelihood of contracting the disease than those who remain unvaccinated.

 

 Jamie Murphy “The vaccine can never duplicate the kind of immunity that we get from nature…When children get the measles after they’ve been vaccinated, they’re getting it from the vaccine and the virus (because there’s so much virus in the vaccine that stays in the body). When their resistance becomes lowered, that can become reactivated. Also, when a natural epidemic of measles occurs, as it does every three to four years in the United States, those children who have been vaccinated, because they did not get a true immunity from the vaccine, become susceptible to measles.”

 Vera Scheibner reports that “In April 1993, the Ministry of Health and Welfare in Japan decided to discontinue the use of measles, mumps, and rubella vaccine (Sawada et al., 1993). This decision was prompted by published reports of vaccinated children and their (unvaccinated) contacts contracting mumps from the MMR vaccine, and reports of one in 1044 vaccinees developing encephalitis.”

 

A study published in 1994 in the Archives of Internal Medicine evaluated all U.S. and Canadian articles reporting measles outbreaks in schools, and found that, on average, 77 percent of all measles cases in these outbreaks were occurring among vaccinated individuals. The authors concluded that “the apparent paradox is that as measles immunization rates rise to high levels in a population, measles becomes a disease of immunized persons.

 

 In 2007, a study performed at the National Institute of Communicable Diseases in South Africa reviewed the increase in mumps outbreaks in the UK and US. In the US, 56,000 cases were reported in 2004-2005. Many of these cases are occurring on college campuses. A mumps outbreak at a New York summer camp found that 96% of those infected had prior vaccination coverage. A similar outbreak in Nova Scotia among vaccinated adolescents and young adults has also been reviewed and it was found that the virus’ genotype was the same as that in the UK and US. These recent outbreaks have raised concerns among scientists about the effectiveness of the mumps vaccine in the MMR. According to the South African scientist, there may be a waning immunity towards mumps in the vaccinated population, which in time could make the vaccine ineffective. Belgian scientists came to the conclusion that the secondary mumps vaccination was a failure during a 2004 outbreak affecting 105 Belgian children from ages 3-12.

 Antibody levels 5 to 6 years after immunization with (the now discredited) high-potency EZ and high-potency Schwarz measles vaccine were insufficient in 40 percent and 50 percent of vaccinated children. The authors concluded, “Given the rapid decline in antibody titers over a 5- to 6-year period in an area where measles vaccine coverage was high, it seems likely that multiple-dose immunization schedules will be needed in the future to maintain protective antibody concentrations….”

 

As a consequence of the fact that antibody response to the vaccine virus is temporary, today we are facing cases of atypical measles occurring in infants under a year old, as well as in older children and in adults. Atypical measles is a severe disease that was first described in the early 70s in children, and later in adolescents and young adults exposed to the wild-type measles virus several years after being vaccinated with the killed or attenuated measles vaccine. The condition is characterized by atypical rash, high fever, cough, headache, and pneumonia. Further complications can include hepatitis, persistence of pulmonary lesions for several years, thrombocytopenia and other circulatory system problems, and cardiac involvement.

 

Another problem found with measles vaccination, documented in several studies, is that it produces immune suppression that contributes to an increased susceptibility to other infections.


The 60% of people who were vaccinated in 1970 have caused many of them to be susceptible to natural measles, because the shots were given too early. This is also why most analyses which profess to have a scientific element, go from the 1973 licensure.

Atypical measles explained by James Cherry: (PMID: 14765342. Page 505).
 
 
 
 
 
 
 

   

 

 
 
 
 
 
 
 
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Measles

     Measles was once considered a harmless childhood disease just like Chicken Pox.  You exposed your child to it so they caught it and ‘got it over with’. No one feared measles, just as they did not fear Chicken Pox.

     The Measles vaccine had a low uptake in the past as parents did not want a vaccine for a virus such as Measles because it was considered self-limiting and benign. Children began receiving the vaccine more widely only after the 1977 Childhood Immunization Initiative  and school vaccine mandates were enforced.

     

     Measles can be a very useful disease in children. They can build a super immune system after having gone through measles. Children with eczema are often cured or relieved of any signs of the condition. Their speech often improves and they go through a maturation process. Many children have been known to make tremendous developmental strides after measles. In the past, when a child was on dialysis, a hospital might have encouraged parents to naturally expose and infect their child with measles because they saw great improvements in the child’s condition.

Even today, the childhood Immunization Initiative is in full force, but it has not stopped Measles from being eliminated.

  

History

 
     From 1963 – 1967 the U.S. had used the killed Measles vaccine. It had a very low uptake which was a good thing in retrospect as it was a disastrous vaccine. It was made with killed measles virus, which skewed the recipient’s immune systems, making them more susceptible to measles after just two years, but in a new form- “atypical measles”.  It was characterized by pneumonia, high fever, atypical rash and a high fatality rate. It was a disease which could be gotten repeatedly.  The vaccine was quickly and silently removed.

 

     A new live vaccine was licensed in 1967, but even that was not used extensively.  At first it was to be given to all infants at approximately 12 months of age. Then it was changed to 6 months, especially if there was measles going around. By 1979, they knew they had problems with this one as well. Babies vaccinated at 6 months of age developed what they called an ‘altered immune response’ which resulted in booster shots at 15 months. Nature published an article which showed that babies under one year of age have very different immune functions and responses than adults do, and simply could not handle the measles vaccine given at that age. It caused immune “energy” rather than an “altered” immune response. Again, these issues were kept quiet and uptake continued to be low. Doctors were encouraged not to report measles cases if possible, so that parents wouldn’t lose confidence in the vaccine. Therefore, you would hear terms such as ‘morbilli-like, or “red measles’.

 

     Since most epidemic outbreaks in the late 1980’s and early 1990’s occurred in  95 – 100% of vaccinated children, a second MMR ‘booster’ vaccine was added to the schedule. By 1990 the actual disease was much rarer, and was simply a continuation of a trend which had been going on right up until the 80’s even in the totally unvaccinated communities. (Clinical Pediatrics). Speaking of Booster shots, do all children need them? No.  The second dose, or booster shot, is to revaccinate the approximated 5% of people for whom the vaccine never worked the first time, also known as primary vaccine failure. That leaves us with roughly 95% getting revaccinated who may never have needed to be. Secondary vaccine failure is due to waning immunity, and even with a second dose schedule in childhood or early adulthood, outbreaks continue to occur in the vaccinated population.

 

 

     Health Departments like to say that keeping unvaccinated children away from vaccinated children will protect vaccinated children. They will also say that vaccines protect children. So isn’t that an oxymoron? If vaccines protect, aren’t they already vaccine ‘protected’?  Unfortunately the answer is no. In 1991 over 60% of Measles cases were in vaccinated children, and cases of Measles continue to occur in the vaccinated.

 

 

     If anyone should be wary of Measles transmission it is the unvaccinated from the vaccinated. Right in the package insert, it states that MMR vaccinated children can excrete Measles Virus and the Mumps virus into the environment. The Chicken Pox vaccine can also be excreted with the MMR-V or Varicella vaccine. Babies, unvaccinated, the immunodeficient, and even older persons can be at risk from newly vaccinated people. Why aren’t parents being told this?

 

 

Detection of measles vaccine in the throat of a vaccinated child.

 

Mumps vaccine virus genome is present in throat swabs obtained from uncomplicated healthy recipients.

 

 Some Basic Facts:

 

     The measles vaccine had nothing to do with the decline in deaths, and has not affected the number of children hospitalized during epidemic years since its introduction.

 

     Concerning the 1991 USA measles outbreak, over half the deaths were in the vaccinated and most deaths were in immunodeficeint people. (Washington Post. June 14, 1991, BMJ, 11 May, 1991). When news reports talk of Measles reported deaths or more serious injury, why don’t they tell the whole truth?

 

     In Africa, children who have a natural measles infection have half the asthma, allergies and eczema compared with their vaccinated peers. (Lancet, June 29, 1996) 
 
 
 

 

 

     The Germans considered the risks of the vaccine too high given  the fact that deaths and disease severity had decreased without any reference to a vaccine.  
 
     In the pre vaccine era, mothers’ antibodies protected babies for at least a year to a year and a half. Measles was mainly an infection of 5 – 9 year olds and by 15 yrs, 99% had antibodies. Today, adults and infants under one year of age are acquiring Measles which can be very serious.
 
     Vaccinated mothers cannot give protective antibodies to their babies, like Mothers’ who have had naturally acquired Measles, can. Therefore, young babies for whom measles can be more serious are no longer protected.  In the pre-vaccine era, babies rarely got measles before 18 months because maternal antibodies were very high as a result of natural immunity. Today maternal antibodies are generally so low from a vaccine that it simply does not prime the immune system like natural infection will. Babies are at risk of getting measles at younger and younger ages, because maternal antibodies no longer last 15 – 18 months. So if there is even the slightest nutritional or immunological problem, babies will have an increased danger from the measles virus, as there is a difference between the immune system of a baby and a toddler. Vaccinated babies who have maternal antibodies, or people who have measles suppressed with gamma globulin, can have a higher rate of  immunoreactive diseases, sebaceous skin diseases, degenerative cartilage,  bone disease, and certain tumors.  (Lancet, 5 Jan 1985) Also see:
Maternal antibodies interfere with measles vaccination.

 

 

     Now think about this…A study published in BMJ years ago found that a select group of children tested, 50% of those with antibodies to measles had never had any clinical disease, and a small subgroup with rising titers also had no clinical symptoms. Non-symptomatic clinical measles was a common entity. This is also shown for Chicken Pox, and several other diseases. To use antibody statistics as proof of either how dangerous or widespread a disease is is a false argument. Measles, like some other diseases, are also dependant upon regular exposure to the bacteria. Which is why in the U.S. Measles is becoming common amongst older adults, who had it clinically as children. Their long term immunity has been jeopardized by the interruption of the bacteria in the environment, so that their levels are no longer automatically boosted every few years.

 

 

 

Measles Basics-

 

     One sign or symptom specific to measles is Koplik Spots which look like bluish-white grains of salt which can be seen on the inside of the cheek, near the second upper molar, but may also be on the gums anywhere in the mouth.  In the early stages there is also cough, runny nose and fever. This will last for a few days. (Medicine International, 1984, pg 20, Viral Diseases in Man, 83rd Edition, pg 412.)

 

     The treatment and cure for Measles is called Vitamin A.  As early as 1932, doctors used cod-liver oil to reduce hospital mortality by 57%.  When antibiotics became the timely treatment, Vitamin A was thrown out, up until the mid-80’s that is. Published studies have found that 72% of hospitalized Measles cases in in the U.S. are Vitamin A deficient. The worse Vitamin A deficiency, the worse the complications and the higher the death rate will be. (Pediatric Nursing, Sept/Oct 1996.)

 

     Measles does not kill children. It is the complications from measles that might attack an already weak immune system. When it knocks down the immune system, the child may become susceptible to other diseases, or develop a secondary infection due to mismanagement of the illness, such as using fever reducing medication, or with a Vitamin A deficiency.  One of the big reasons why third world children suffer from complications of measles and other diseases can be viewed here

 


     Vaccinations will always be the higher priority. The focus will be on vaccinating as many as they can and fixing the cause of death is secondary to vaccination. If these children were properly nourished and had access to clean water, they wouldn’t be dying. The substitution of vaccination over proper nutrition, sleep, clean water, etc., will not prevent more serious illness or death.

 

     There will be some who will say the theory of herd immunity is real, that Measles has declined due to a vaccine; deaths have been prevented, etc. However, when you factor in mild and subclinical cases which often are not counted, what have we really prevented? Incidence data ignores these cases which make it appear to be something it may very well not be. What about the number of deaths and injury from the vaccine itself? Maybe a financial cost factor needs to be done between treating naturally acquired Measles vs. the injuries and death associated with the vaccine.

 

Speaking of which…MMR and MMR-V coming soon!